On the heels of similar investment pledges from Eli Lilly and Johnson & Johnson, Switzerland’s Novartis is stepping up to the ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Swiss pharmaceutical company, Novartis, has announced plans to build a new, $1.1 billion biomedical research complex in San ...

The Swiss pharmaceutical giant plans to build seven new facilities and expand others in an effort that will allow it to ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from the Trump ...

Swiss pharma group Novartis has said it will expand its US manufacturing and research and development with a $23bn investment over five years, as drugmakers reconfigure their supply chains as part of ...

Following the firm’s $1.75bn acquisition of radiopharmaceuticals company Mariana Oncology and the $745m deal with Ratio ...

It joins a growing number of multinational drug companies to announce investments in the US. Read more at straitstimes.com.

Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United ...

Novartis (NVS, Financials) is investing $23 billion over the next five years to expand its manufacturing and research ...

Swiss pharmaceutical giant Novartis announced Thursday that it plans to build a $1.1 billion research hub in San Diego as ...